About this Research Topic
The field of drug development is a time-consuming and costly process, with the development of individual pharmaceutical products estimated to take between 11 and 14 years and cost between 161-1,800 million dollars. This has led to the rise of drug repositioning, where existing drugs are tested against diseases unrelated to their initial use, as a prominent area in pharmacology. This approach is particularly relevant in the fight against cancer, a multifactorial disease where single molecular mechanisms, pathways, or biomarkers are often associated with a wide range of tumor types. The use of well-characterized, non-cancer drugs as potential anticancer agents has increased, often in combination with existing chemotherapeutics or other repurposed agents. However, there is a need for further research to advance these interventional approaches and introduce them into clinical practice to improve treatments for cancer patients.
The goal of this research topic is to explore the effects of repurposed drugs or drug repurposing candidates on cancer signaling pathways. This includes both in vitro and in vivo studies, as well as computational approaches. The research aims to provide information about the antitumor effectiveness of a diverse range of non-cancer compounds, through preclinical experiments, clinical trials, and observational studies. The aim is to improve oncologic therapies by providing clinical insights into repurposed drugs targeting cancer signaling pathways.
The scope of this research topic is limited to studies that provide information about the effects of repurposed drugs or drug repurposing candidates on cancer signaling pathways. We welcome articles addressing, but not limited to, the following themes:
- The use of bioinformatics platforms to analyze the effect of potentially repositioned drugs
- The application of cutting-edge molecular technologies, such as liposomes and CRISPR-Cas9, in the study of repurposed drugs
- Preclinical experiments that test the antitumor effectiveness of non-cancer compounds
- Clinical trials and observational studies that provide insights into the use of repurposed drugs in oncologic therapies.
Please note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases, which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo), are out of scope for this section and will not be accepted as part of this Research Topic.
The goal of this research topic is to explore the effects of repurposed drugs or drug repurposing candidates on cancer signaling pathways. This includes both in vitro and in vivo studies, as well as computational approaches. The research aims to provide information about the antitumor effectiveness of a diverse range of non-cancer compounds, through preclinical experiments, clinical trials, and observational studies. The aim is to improve oncologic therapies by providing clinical insights into repurposed drugs targeting cancer signaling pathways.
The scope of this research topic is limited to studies that provide information about the effects of repurposed drugs or drug repurposing candidates on cancer signaling pathways. We welcome articles addressing, but not limited to, the following themes:
- The use of bioinformatics platforms to analyze the effect of potentially repositioned drugs
- The application of cutting-edge molecular technologies, such as liposomes and CRISPR-Cas9, in the study of repurposed drugs
- Preclinical experiments that test the antitumor effectiveness of non-cancer compounds
- Clinical trials and observational studies that provide insights into the use of repurposed drugs in oncologic therapies.
Please note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases, which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo), are out of scope for this section and will not be accepted as part of this Research Topic.
Keywords: drug repositioning, cancer, signaling pathways, treatments
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
